These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


300 related items for PubMed ID: 32108749

  • 21. The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction.
    van Hout GP, Bosch L, Ellenbroek GH, de Haan JJ, van Solinge WW, Cooper MA, Arslan F, de Jager SC, Robertson AA, Pasterkamp G, Hoefer IE.
    Eur Heart J; 2017 Mar 14; 38(11):828-836. PubMed ID: 27432019
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of NLRP3 inflammasome alleviates cognitive deficits in a mouse model of anti-NMDAR encephalitis induced by active immunization.
    Yang X, Sun A, Kong L, Yang X, Zhao X, Wang S.
    Int Immunopharmacol; 2024 Aug 20; 137():112374. PubMed ID: 38851162
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. NLRP3 regulates alveolar bone loss in ligature-induced periodontitis by promoting osteoclastic differentiation.
    Chen Y, Yang Q, Lv C, Chen Y, Zhao W, Li W, Chen H, Wang H, Sun W, Yuan H.
    Cell Prolif; 2021 Feb 20; 54(2):e12973. PubMed ID: 33382502
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis.
    McElvaney OJ, Zaslona Z, Becker-Flegler K, Palsson-McDermott EM, Boland F, Gunaratnam C, Gulbins E, O'Neill LA, Reeves EP, McElvaney NG.
    Am J Respir Crit Care Med; 2019 Dec 01; 200(11):1381-1391. PubMed ID: 31454256
    [Abstract] [Full Text] [Related]

  • 31. Pharmacological suppression of NLRP3 inflammasome attenuated the development of autoimmune thyroiditis.
    Ding H, Sun X, Xu H.
    Cell Immunol; 2023 Feb 01; 384():104659. PubMed ID: 36608372
    [Abstract] [Full Text] [Related]

  • 32. NLRP3 inflammasome activates interleukin-23/interleukin-17 axis during ischaemia-reperfusion injury in cerebral ischaemia in mice.
    Wang H, Zhong D, Chen H, Jin J, Liu Q, Li G.
    Life Sci; 2019 Jun 15; 227():101-113. PubMed ID: 31002919
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review.
    Wu D, Chen Y, Sun Y, Gao Q, Li H, Yang Z, Wang Y, Jiang X, Yu B.
    Inflammation; 2020 Feb 15; 43(1):17-23. PubMed ID: 31646445
    [Abstract] [Full Text] [Related]

  • 35. Evidence against a role for NLRP3-driven islet inflammation in db/db mice.
    Kammoun HL, Allen TL, Henstridge DC, Barre S, Coll RC, Lancaster GI, Cron L, Reibe S, Chan JY, Bensellam M, Laybutt DR, Butler MS, Robertson AAB, O'Neill LA, Cooper MA, Febbraio MA.
    Mol Metab; 2018 Apr 15; 10():66-73. PubMed ID: 29478918
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The selective Nlrp3 inflammasome inhibitor Mcc950 attenuates lung ischemia-reperfusion injury.
    Xu KY, Wu CY, Tong S, Xiong P, Wang SH.
    Biochem Biophys Res Commun; 2018 Sep 18; 503(4):3031-3037. PubMed ID: 30146255
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
    Schuh E, Groß CJ, Wagner D, Schlüter M, Groß O, Kümpfel T.
    Clin Immunol; 2019 Jun 18; 203():45-52. PubMed ID: 30974290
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 15.